Novo Nordisk A/S
Moderna strikes deal to develop mRNA drugs in China
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Wednesday said it struck a deal with Chinese officials to research, develop and manufacture messenger RNA medicines in the country, despite rising tensions between the U.S. and China. The Massachusetts-based biotech company signed a memorandum of understanding and a related land collaboration deal to develop drugs […]
Read More
People should stop taking Ozempic, Wegovy obesity drugs before surgery, doctors group says
In this photo illustration, a box of the diabetes drug Ozempic rests on a pharmacy counter on April 17, 2023 in Los Angeles, California. Mario Tama | Getty Images People on diabetes and weight loss drugs such as Novo Nordisk‘s Ozempic and Wegovy should stop taking them before having elective surgery to reduce the risk […]
Read More
As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge
An Eli Lilly & Co. logo is seen on a box of insulin medication in this arranged photograph at a pharmacy in Princeton, Illinois. Daniel Acker | Bloomberg | Getty Images Drugmakers are jockeying to capitalize on the next major innovation coming to the blockbuster weight loss industry: effective, convenient and potentially affordable obesity pills. […]
Read More
Eli Lilly’s weight loss drugs trounce sky-high expectations, boosting the stock
Eli Lilly bested investors’ super-high expectations at the American Diabetes Association conference this week, cementing its leadership in metabolic medicine and prompting Wall Street analysts to take another look at their sales forecasts. Across the board, analysts said the news is likely to lend support Lillto y shares, which have already popped more than 26% […]
Read More
Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly’s experimental drug helped patients lose up to 24% of their weight after almost a year, the highest reduction seen in the obesity treatment space to date, according to new mid-stage clinical trial results released Monday. […]
Read More
Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss
Novo Nordisk said that it was cutting the supply of some doses of its popular obesity drug in the U.S. as it struggles to keep up with surging demand. Liselotte Sabroe | Afp | Getty Images Novo Nordisk‘s high-dose experimental obesity pill helped overweight or obese adults lose around 15% of their body weight, according […]
Read More
Pfizer to end development of experimental obesity pill due to elevated liver enzymes
Pavlo Gonchar | Lightrocket | Getty Images Pfizer on Monday said it would stop developing its experimental obesity and diabetes pill, lotiglipron, due to elevated liver enzymes in patients who took the drug once a day in mid-stage clinical studies. Those elevated enzymes often indicate damage to cells in the liver, but the pharmaceutical giant […]
Read More
Novo Nordisk sues clinics allegedly selling knockoff versions of Ozempic and Wegovy
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. Mario Tama | Getty Images Novo Nordisk on Tuesday sued five medical spas and wellness clinics for allegedly selling cheaper, unauthorized versions of the company’s weight loss drugs Ozempic and Wegovy. The […]
Read More
This veteran investor’s funds have been outperforming because 2006. Listed here are his best investing recommendations
Less costly, quicker-rising, and of a higher quality than the rest of the industry. Those people are the qualities that outperforming portfolio supervisor Jordan Cvetanovski has looked for in shares for the earlier approximately 20 years. And the final results have tested to be steady throughout the world-wide monetary disaster, the era of zero fascination […]
Read More
Credit Suisse sees Eli Lilly headed higher as Mounjaro users espouse weight loss drug on social media
You can’t deny the buzz. Credit Suisse analyst Trung Huynh has combed through social media and is impressed by the awareness — and demand — for GLP-1 medications such as Eli Lilly ‘s Mounjaro. “Although we caution posts may have responder bias, and comments are in the public domain and unconfirmed, nonetheless we have parsed […]
Read More